Inulin * a potential preventive dietary supplement against PPI induced hypomagnesemia

Inulin * a potential preventive dietary supplement against PPI induced hypomagnesemia - Inulin rescue trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38331

Enrollment

Registered

2014-02-27

Start date

2014-01-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypomagnesemia magnesium shortage PPI induced hypomagmagnesemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The use of PPIs (protonpump inhibitors, type omeprazol) and having hypomagnesemia as defined by serum Mg2+

Exclusion criteria

Exclusion criteria: Unstable health conditions, patients that have stopped the PPI, acutely ill patients.

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: Main study parameter is serum Mg2+. PPI*s exert their negative effect on serum Mg2+ in brisk manner and is influenced by the overall Mg2+ status of the patient. Mg2+ depleted individuals react to PPI-challenge within 4-5 days and gradually develop hypomagnesemia (serum Mg2+ 1.1mmol) is second endpoint because it can be indicative for renal failure or the use of antacids. (7) Moreover, severe adverse reactions within trial periods irrespective of origin will lead to immediate stop of intervention or alternative treatment.	—

Measure

Time frame

Main study parameters/endpoints: Main study parameter is serum Mg2+. PPI*s exert their negative effect on serum Mg2+ in brisk manner and is influenced by the overall Mg2+ status of the patient. Mg2+ depleted individuals react to PPI-challenge within 4-5 days and gradually develop hypomagnesemia (serum Mg2+ 1.1mmol) is second endpoint because it can be indicative for renal failure or the use of antacids. (7) Moreover, severe adverse reactions within trial periods irrespective of origin will lead to immediate stop of intervention or alternative treatment.

—

Countries

Netherlands

Outcome results